HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women
M. J. van der Mooren MD, PhD, Department of Obstetrics and Gynecology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands.
Tel: +31 (0) 20 4443244; fax: +31 (0) 20 4444422; e-mail: mj.vandermooren@VUmc.nl
No abstract is available for this article.